MetaCap

Aclaris Therapeutics (ACRS) vs Climb Bio (CLYM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Climb Bio (CLYM) has outperformed Aclaris Therapeutics (ACRS) over the past year, gaining 440.6% versus a gain of 37.1%. Over five years, CLYM leads with a -33.2% price change compared with -72.7% for ACRS. Aclaris Therapeutics is the larger company by market cap ($545.6 million vs $539.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACRS+37.05%CLYM+440.59%
+997%+473%-51%
Nov 21, 20251 yearNov 20, 2026
ACRS-75.05%CLYM-48.46%
+40%-30%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACRS versus CLYM key metrics
MetricACRSCLYM
Share price$3.44$9.19
Market cap$545.63M$539.80M
1-day change-1.71%-0.97%
YTD return+14.29%+129.75%
1-year return+37.05%+440.59%
5-year return-72.74%-33.21%
EPS (TTM)$-0.59$-0.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.83M—
Revenue growth (YoY)-58.19%—
Net income (latest FY)$-64.92M$-59.85M
Gross margin73.28%—
Operating margin-975.91%—
Net margin-829.58%—
52-week high$6.60$18.33
52-week low$2.46$1.64
Distance from 52-week high-47.88%-49.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+205.23%+209.03%
Average volume3.07M1.38M
Shares outstanding158.61M58.74M
Employees6928
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CLYM has outperformed ACRS by 403.5 percentage points over the past year.

About Aclaris Therapeutics

ACRS stock →

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Climb Bio

CLYM stock →

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

ACRS vs CLYM FAQ

Which is bigger, Aclaris Therapeutics or Climb Bio?

Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $545.63M compared with $539.80M for Climb Bio (CLYM).

Which stock has performed better over the past year, ACRS or CLYM?

CLYM returned +440.59% over the past 12 months, compared with +37.05% for ACRS (price return, excluding dividends). Past performance does not predict future results.

Are Aclaris Therapeutics and Climb Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons